The board of Strides Pharma Science has given the green light to a scheme of arrangement among its group entities, aimed at creating a distinct contract development and manufacturing entity called “OneSource.” This arrangement involves the demerger of Strides Pharma Science’s CDMO and soft gelatin business into Stelis, in addition to the demerger of Continue Reading
